Newsroom

Posters

  • November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
  • August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
  • July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
  • May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
  • March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD
More posters

Newsroom

N30 Newsroom

  • March 13, 2013
    N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis

    Boulder, Colo., March 13, 2013–N30 Pharmaceuticals, Inc. (“N30 Pharma”) a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF).

    The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation, the most common and serious form of CF.

    The clinical study announced today is being conducted in collaboration with the Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN), and the lead principal investigator for the study is Scott Donaldson, M.D., at The University of North Carolina, Chapel Hill. More…PDF (134Kb)

  • October 8, 2012
    N30 Names Sherif Gabriel, Ph.D. as VP Research

    Boulder, Colo., October 8, 2012 –N30 Pharmaceuticals, Inc. today announced the addition of Dr. Sherif Gabriel to its senior leadership team.

    Prior to joining N30 Pharma, Dr. Gabriel was on the faculty of the University of North Carolina Cystic Fibrosis Center, Director of the Cystic Fibrosis Correction Core of the Center, and Associate Professor in the Department of Pediatrics, Division of Pulmonology.

    Dr. Gabriel’s career has revolved around the molecular regulation of ion and fluid balance in the human lung and gastrointestinal tract. More…PDF (30Kb)

  • August 27, 2012
    N30 Pharma Converts from LLC to C-Corp

    Boulder, Colo., August 27, 2012 –N30 Pharmaceuticals, Inc. today announced that it has converted from a Delaware limited liability company to a Delaware corporation. Coincident with this transition, N30 Pharma completed a round of financing, led by Deerfield Management.. More…PDF (27Kb)

  • February 21, 2012
    N30 Pharma Names Evan Loh, MD and John R. Moore to Board of Directors

    Boulder, Colo., February 21, 2012 –N30 Pharmaceuticals, LLC today announced the addition of two new outside director members to its Board of Directors, Dr. Evan Loh and Mr. John Moore. More…PDF(38Kb)

  • September 8, 2010
    N30 Announces Initiation of Phase 1 Trials of Novel Reductase Inhibitor

    Boulder, Colo., September 8, 2010 –N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

    N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions. More… PDF (34kb)